PND19 Budget IMPACT Modelling for Alemtuzumab in Relapsing-Remitting Multiple Sclerosis Patients in Colombia

Londono, S; Gómez, Natalia García

doi:10.1016/j.jval.2020.08.1344

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, 73 studies and 25 HTA reports were cost-utility analyses, 16 studies were cost-effectiveness analyses, five studies and three HTAs were cost-minimization analyses [23][24][25][26][27][28][29][30], and six studies were budget impact analyses [31][32][33][34][35][36]. Furthermore, 17 studies comprised multiple economic evaluations [18,22,[37][38][39][40][41][42][43][44][45][46][47][48][49][50][51], six were cost-consequences analyses [52-57], two were cost-saving analyses [58, 59], one was a cost-benefit analysis [60], and one was a costoffset analysis [61].…”

Section: Study Characteristicsmentioning

confidence: 99%

How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review

Wiyani¹,

Badgujar

Khurana³

et al. 2021

Neurol Ther

View full text Add to dashboard Cite

Introduction: The introduction of diseasemodifying therapies (DMTs) for relapsing multiple sclerosis (RMS) over the last two decades has prompted the economic assessments of these treatments by reimbursement authorities. The aim of this systematic literature review was to evaluate the modeling approach and data sources used in economic evaluations of DMTs for RMS, identify differences and similarities, and explore how economic evaluation models have evolved over time. Methods: MEDLINEÒ, EmbaseÒ, and EBM Reviews databases were searched using OvidÒ Platform from database inception on 25 December 2019 and subsequently updated on 17 February 2021. In addition, health technology assessment agency websites, key conference proceedings, and gray literature from relevant

show abstract